key: cord-0779293-y62z2j1b
authors: Turner-Stokes, Tabitha; Jiang, Elina; Johnson, Nathan; Khakhria, Kanay; Kong, Edmund; Cairns, Tom; Clarke, Candice; Greathead, Louise; Griffith, Megan; Guckian, Mary; Kelleher, Peter; McClure, Myra O.; Prendecki, Maria; Rosadas, Carolina; Tedder, Richard; Lightstone, Liz; Willicombe, Michelle; McAdoo, Stephen P.
title: Serological screening for COVID-19 in patients with glomerular disease
date: 2021-02-12
journal: Kidney Int Rep
DOI: 10.1016/j.ekir.2021.02.006
sha: 4aef0d3b632be6e9b7fba2ad33c3ddcc0a01e827
doc_id: 779293
cord_uid: y62z2j1b

nan

The incidence, clinical features and severity of SARS-CoV-2 infection amongst immunosuppressed patients with glomerular disease are not well-described.

During the initial outbreak of SARS-CoV-2 infection in the UK, as PCR testing for SARS-CoV-2 was widely available in hospital settings, but not in the community, patients with mild disease generally did not receive diagnostic testing. Thus, identification of COVID-19 based on PCR testing alone under-estimates infection rates, and may bias interpretation of clinical outcomes, representing only those patients who have severe disease.

Assessing true rates of COVID-19 within patient populations requires a combination of PCR testing at the time of disease presentation, and subsequent serological testing for SARS-CoV-2 infection. There are a large number of assays available to detect antibodies to SARS-CoV-2 S1-S6 , though data on their performance in immunosuppressed patient populations are limited.

The aims of this study were to estimate the incidence of SARS-CoV-2 infection within a large cohort of patients with glomerular disease; to report their clinical features and outcomes; and to describe our experience in using two different serological assays to identify antibodies to SARS-CoV-2 in these patients.

J o u r n a l P r e -p r o o f

We identified ten patients within our clinic cohort of approximately 1500 patients who had PCR-proven COVID-19 (Table 1) . Nine were receiving immunosuppression at the time of diagnosis, seven with two or more agents ( Figure S1A ). Most patients (70%) were B-cell deplete following recent rituximab treatment and/or on corticosteroids. Eight patients required hospital admission and three died ( Figure S1B&C ). Of the 3 patients who died, one was admitted to ITU and the other two died on a general ward.

All seven patients who survived received subsequent serology testing using the Abbott SARS-CoV-2 IgG assay. The mean interval between PCR result and serological testing was 86 days (range 55-145). Five patients tested positive, two negative (mean IgG titre 3.90 RLU).

One of the two negative patients re-tested with the S-protein/RBD DABA assay (using the same serum samples) was positive. Thus, six of the seven surviving patients seroconverted following PCR-proven SARS-CoV-2 infection.

A total of 493 patients were screened for antibodies to SARS-CoV-2 using the N-proteinbased Abbott IgG assay. Thirty-one patients (6.3%) had positive (IgG titre >1.4 RLU) and 29 (5.9%) had indeterminate serology (IgG titre 0.25-1.3 RLU). Indeterminate samples were reprocessed using the S-protein/RBD DABA assay, identifying a further 7 patients with J o u r n a l P r e -p r o o f positive serology ( Figure 1 ). Hence, a total of 38/493 patients (7.7%) in our cohort had serological evidence of previous SARS-CoV-2 infection.

Patients were analysed in three groups according to serology status ( Figure 1 ): Positive on Abbott assay ("Abbott+"), indeterminate on Abbott but positive on S-protein/RBD DABA assay ("RBD+"), indeterminate on Abbott and negative on S-protein/RBD DABA assay ("RBD-"). Five out of the 7 patients with PCR-proven COVID-19 who received subsequent serology testing for SARS-CoV-2 were positive on the Abbott assay and are included in the Abbott+ group in this section. Surprisingly, the remaining two patients were negative (rather than indeterminate) on the Abbott assay (although one was subsequently positive on the RBD assay) and were not included in the analysis of these three serological groups.

Most patients in the Abbott+ and RBD+ groups reported prior COVID-19 symptoms, whereas the RBDgroup was largely asymptomatic ( Table 1 ). The majority of symptomatic patients reported onset of symptoms within a month before or after UK 'lockdown' on the 23 rd March 2020 ( Figure S2A ). Fever, cough, anosmia and fatigue were the most commonly reported symptoms ( Figure S2B ). Overall disease severity was notably milder compared to the PCR positive group (Table 1) . A greater proportion of patients in the Abbott+ group had moderate disease, compared to the RBD+ group. Conversely, patients with moderate disease developed higher IgG titres to SARS-CoV-2 (Abbott), compared to patients with mild or asymptomatic disease ( Figure S3A ).

IgG titres to SARS-Cov-2 (Abbott) were significantly higher in the RBD+ compared to the RBD-group ( Figure S3B ). The absence of positive serology on either immunoassay, J o u r n a l P r e -p r o o f combined with low incidence of COVID-19 symptoms in the RBD-group, suggest that these patients did not have prior infection with SARS-CoV-2.

The Abbott+ and RBD+ groups were compared to determine factors which may have contributed to the difference in performance of the Abbott IgG assay. More patients in the RBD+ group were receiving immunosuppression with multiple agents at the time of testing (Table 1) . However, there was no difference in patient age, male:female ratio, or in the time interval between symptom onset and serological testing ( Figure S4 ).

Using a combination of PCR and serological testing, we identified 43 patients who had COVID-19. This overall analysis included the 38 patients with positive SARS-CoV-2-serology (which includes the 5 PCR positive patients who had positive serology using the Abbott assay), combined with the remaining 5 PCR positive patients. Nineteen patients (44%) were male, 24 (56%) female, and their mean age was 49 years. Thirty-one patients (72%) were receiving immunosuppression, 11 (26%) with two or more agents.

With respect to overall disease severity: 6 (14%) were asymptomatic, 26 (60%) had mild disease that did not require hospital admission, 8 (19%) required hospital admission but were subsequently discharged, and a further 3 patients (7%) were admitted to hospital and died during admission. 

CoV-2 infection rate in our cohort. Moreover, analysis of disease severity and clinical outcome in either PCR-proven or serologically-proven groups in isolation is subject to selection bias because patients receiving PCR testing were more likely to be hospitalised, and serology testing excludes patients who died from COVID-19. A combined analysis of all cases (identified either by PCR or serological testing) showed that the majority of patients had mild or asymptomatic disease, 19% required hospital admission (but subsequently recovered and were discharged), and the overall case fatality rate was 7% (substantially lower than the 30% mortality reported for the PCR-proven group). This provides a more Icelandic epidemiological study reported that, out of 1797 patients identified with SARS-CoV-2 infection (with a similar male:female ratio and average age to our patient cohort), 5.6% were hospitalised, 1.5% required admission to ITU and 0.6% died 1 . Further work is now needed to understand the role of different immunosuppressive treatments, the underlying disease for which they are prescribed, and co-morbidities, in determining COVID-19 outcome. Seroprevalence was 7.7% in our cohort, which was lower than that reported in London over the course of the study period (10-15%), 2 but higher than expected in a vulnerable cohort of patients who were advised to take strict 'shielding' measures during the pandemic. We note, however, that that all but one of the PCR-or serologically-proven infections occurred with 4 weeks of this recommendation and the introduction of national 'lockdown' ( Figure   S2A ). The overall rate of infection was also significantly lower than in the haemodialysis population at our centre (36%), who were similarly vulnerable but unable to 'shield' due to their need to attend in-centre haemodialysis 3 . This suggests that shielding recommendations, though not completely effective, did impact rates of infection in our patient group. The S-protein/RBD DABA assay identified seroconversion to SARS-CoV-2 in 28% of patients testing indeterminate on the Abbott assay. The difference in performance between these two assays may be due to differences in the immunogenicity of the N-protein compared to the S-protein RBD [4] [5] [6] . Notably, patients with asymptomatic or mild disease had a weaker serological response compared to those with moderate disease, confirming previous reports 4, [7] [8] [9] . Thus, an RBD antigen-based assay may be more sensitive for assessing seroconversion in immunosuppressed patients, particularly for those that have mild disease, or those on multiple immunosuppressive agents.

We believe this is the first study to perform systematic serological screening on a large cohort of patients with glomerular disease, providing a representative analysis of COVID-19 disease characteristics and severity in this immunosuppressed population and demonstrating, somewhat reassuringly, that many patients had mild illness. We compared the performance of two different serological tests for SARS-CoV-2 and propose that an RBD antigen-based immunoassay is preferred in immunosuppressed patients. This should be considered in future studies performing serological screening in these patients, and in clinical practice. Supplementary references, and Supplementary information is available at KI Report's website. Figure 1 : Flow diagram of serological screening A total of 493 patients attending their planned clinic appointments received serological testing for SARS-CoV-2 during the study period. Flow diagram indicates the number of patients who tested positive, indeterminate or negative using the Abbott SARS-CoV-2 IgG assay. Serum samples with an indeterminate test result on the Abbott assay were reprocessed using the S-protein/RBD hybrid DABA assay and the number of positive and negative results from this second assay are indicated. The three serological groups that underwent subsequent comparative analysis are indicated (Abbott+, RBD+ and RBD-).

J o u r n a l P r e -p r o o f

Clinical spectrum of coronavirus disease 2019 in Iceland: population based cohort study

Weekly COVID-19 Surveillance Report (Week 29). Available at

High Prevalence of Asymptomatic COVID-19 Infection in Hemodialysis Patients Detected Using Serologic Screening

Detection of antibodies to the SARS-CoV-2 spike glycoprotein in both serum and saliva enhances detection of infection. medRxiv

Evaluation of a novel multiplexed assay for determining IgG levels and functional activity to SARS-CoV-2

Testing for responses to the wrong SARS-CoV-2 antigen? The Lancet

Are we underestimating seroprevalence of SARS-CoV-2?

Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections